To the Editor Dr Smith and colleagues1 noted that “there appears to be little support for such a radical approach at least at present” in regard to the current situation facing combination therapies for cardiovascular disease prevention. However, the authors failed to outline any of the valid reasons behind this limited support, especially when focused on primary prevention. They instead quoted supply-side barriers and resistance due to the inevitable imperfect titration of individual therapies as the main culprits.
Dalton ARH. Polypill for Cardiovascular Disease Prevention. JAMA. 2013;310(7):749. doi:10.1001/jama.2013.16367